Post by Daniella Kranjac

No therapeutic. No clinical asset. No molecule. Merck KGaA just agreed to buy Bio-Techne for $11.3B, their biggest life science tools acquisition since Sigma-Aldrich a decade ago. A 36% premium for: 6,000 proteins, 425,000 antibodies, instruments, multi-omics and spatial biology workflows.Merck is buying additional infrastructure that enables drug discovery and manufacturing: The invisible layer of biopharma. And it's exactly where we invest at AVANT BIO — it's not a coincidence the strategics keep writing checks in this sector. Every biotech and pharma company depends on these tools and technologies, every day, regardless of what therapy succeeds in the clinic. I've watched this category go from "unglamorous" in the 90's to the most defensible investment in biopharma. $11B is just the latest validation of our sector. Exciting times ahead! https://lnkd.in/gjrj73a4